JP Morgan Chase Portfolio holdings
JPMorgan Chase & Co., formed by the 2000 merger of J.P. Morgan & Co. and Chase Manhattan Bank, is a global financial services giant headquartered in New York City, tracing its roots back to 1799 through its predecessor firms. As one of the largest banks in the world, it operates across investment banking, commercial banking, asset management, and consumer banking, managing trillions in assets and serving millions of customers, corporations, and governments. Led by CEO Jamie Dimon since 2005, the firm is renowned for its role in high-profile deals, robust trading operations, and its Chase retail banking network, which includes extensive credit card and mortgage services. Combining a legacy of financial innovation with a dominant market presence, JPMorgan Chase remains a cornerstone of the global economy.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Broadcom
AVGO
|
+$3.21B |
| 2 |
Arthur J. Gallagher & Co
AJG
|
+$2.24B |
| 3 |
Walt Disney
DIS
|
+$2.18B |
| 4 |
Walmart Inc
WMT
|
+$1.96B |
| 5 |
McDonald's
MCD
|
+$1.91B |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Eli Lilly
LLY
|
+$2.77B |
| 2 |
JPMorgan BetaBuilders Europe ETF
BBEU
|
+$2.64B |
| 3 |
Vanguard Long-Term Treasury ETF
VGLT
|
+$2.5B |
| 4 |
iShares Broad USD High Yield Corporate Bond ETF
USHY
|
+$2.23B |
| 5 |
State Street SPDR S&P 500 ETF Trust
SPY
|
+$2.06B |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Miscellaneous | 24.61% |
| 2 | Technology | 23.17% |
| 3 | Financials | 10.12% |
| 4 | Consumer Discretionary | 9.84% |
| 5 | Healthcare | 7.97% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | Held Since | |
|---|---|---|---|---|---|---|---|
3826
Invesco Actively Managed Exch-Traded Commodity Fd Tr Invesco Optimum Yield Diversified Commodity Strategy No K-1 ETF
PDBC
$7.78B
| $2.53M | ﹤0.01% |
194,503
-312,369
| -62% | -$4.21M |
2021 Q1
15 quarters
|
|
3827
CALL
Zscaler
ZS
$32.1B
| $2.53M | ﹤0.01% |
14,000
+1,500
| +12% | +$290K |
2024 Q3
1 quarter
|
|
|
AUTL
3828
Autolus Therapeutics
AUTL
$474M
| $2.52M | ﹤0.01% |
1,071,533
-213,175
| -17% | -$721K |
2019 Q4
20 quarters
|
|
3829
Myers Industries
MYE
$1.19B
| $2.51M | ﹤0.01% |
227,635
+94,129
| +71% | +$1.13M |
2013 Q2
46 quarters
|
|
3830
PUT
DraftKings
DKNG
$9.23B
| $2.51M | ﹤0.01% |
67,500
+17,500
| +35% | +$694K |
2024 Q3
1 quarter
|
|
3831
Fidelity Fundamental Large Cap Growth ETF
FFLG
$645M
| $2.51M | ﹤0.01% |
100,110
-4,525
| -4% | -$113K |
2024 Q1
3 quarters
|
|
3832
Vanguard S&P Small-Cap 600 Growth ETF
VIOG
$1.04B
| $2.51M | ﹤0.01% |
21,573
-9,687
| -31% | -$1.18M |
2023 Q2
6 quarters
|
|
|
BEAGU
3833
Bold Eagle Acquisition Corp Units
BEAGU
| $2.51M | ﹤0.01% |
+248,906
| New | +$2.5M |
2024 Q4
0 quarters
|
|
3834
MetroCity Bankshares
MCBS
$1.01B
| $2.5M | ﹤0.01% |
78,276
+35,118
| +81% | +$1.14M |
2019 Q4
20 quarters
|
|
3835
Goldman Sachs ActiveBeta International Equity ETF
GSIE
$5.88B
| $2.5M | ﹤0.01% |
74,889
-8,193
| -10% | -$283K |
2019 Q3
21 quarters
|
|
3836
Oaktree Specialty Lending
OCSL
$1.05B
| $2.5M | ﹤0.01% |
163,387
+82,464
| +102% | +$1.32M |
2022 Q3
9 quarters
|
|
3837
Titan Machinery
TITN
$598M
| $2.5M | ﹤0.01% |
176,652
+3,626
| +2% | +$52.5K |
2015 Q4
36 quarters
|
|
3838
Summit Therapeutics
SMMT
$13.4B
| $2.49M | ﹤0.01% |
139,581
-23,068
| -14% | -$447K |
2020 Q3
17 quarters
|
|
|
RGEF
3839
Rockefeller Global Equity ETF
RGEF
$833M
| $2.48M | ﹤0.01% |
+100,409
| New | +$2.52M |
2024 Q4
0 quarters
|
|
3840
PUT
PENN Entertainment
PENN
$1.98B
| $2.48M | ﹤0.01% |
125,000
+116,300
| +1,337% | +$2.29M |
2024 Q3
1 quarter
|
|
3841
Bar Harbor Bankshares
BHB
$661M
| $2.48M | ﹤0.01% |
81,000
+30,084
| +59% | +$995K |
2017 Q3
29 quarters
|
|
3842
Invesco Water Resources ETF
PHO
$1.9B
| $2.47M | ﹤0.01% |
37,583
-12,651
| -25% | -$882K |
2017 Q4
28 quarters
|
|
3843
PUT
Remitly
RELY
$4.61B
| $2.46M | ﹤0.01% |
+109,200
| New | +$2.01M |
2024 Q4
0 quarters
|
|
|
MTLS
3844
Materialise
MTLS
$490M
| $2.46M | ﹤0.01% |
349,346
+308,108
| +747% | +$2.04M |
2023 Q4
4 quarters
|
|
3845
CALL
Vaxcyte
PCVX
$8.4B
| $2.46M | ﹤0.01% |
30,000
| – | – |
2024 Q3
1 quarter
|
|
|
3846
PUT
Vaxcyte
PCVX
$8.4B
| $2.46M | ﹤0.01% |
30,000
-13,000
| -30% | -$1.29M |
2024 Q3
1 quarter
|
|
3847
CALL
Scorpio Tankers
STNG
$4.32B
| $2.45M | ﹤0.01% |
+49,400
| New | +$2.82M |
2024 Q4
0 quarters
|
|
3848
iShares S&P 500 BuyWrite ETF
IVVW
$345M
| $2.45M | ﹤0.01% |
50,000
| – | – |
2024 Q1
3 quarters
|
|
3849
PUT
Enovix
ENVX
$614M
| $2.45M | ﹤0.01% |
257,371
| – | – |
2024 Q2
2 quarters
|
|
3850
Global X MSCI Argentina ETF
ARGT
$707M
| $2.45M | ﹤0.01% |
29,581
+10,067
| +52% | +$781K |
2023 Q4
4 quarters
|
|
Similar funds
JP Morgan Chase's Q4 2024 Portfolio in Review
As of Q4 2024, JP Morgan Chase held 7,917 positions worth $1.34T, up 2.1% from $1.32T the previous quarter. Its ten largest holdings account for 24% of the portfolio.
JP Morgan Chase's Q4 2024 filing shows 509 new, 3,351 increased, 2,465 reduced and 522 closed positions. Its largest new stake was Primo Brands: 3,989,501 shares worth $123M. The largest sale was Eli Lilly, an estimated $2.77B.
By sector, the portfolio is most concentrated in Miscellaneous at 25% of assets, up from 24% a quarter earlier, followed by Technology and Financials.
- JP Morgan Chase's largest Q4 2024 buy was Primo Brands: 3,989,501 shares worth $123M.
- JP Morgan Chase added most to Broadcom in Q4 2024, an estimated $3.21B increase.
- JP Morgan Chase's biggest Q4 2024 reduction was Eli Lilly, cutting an estimated $2.77B.
- JP Morgan Chase fully exited Stericycle Inc in Q4 2024, selling an estimated $183M.
- JP Morgan Chase's ten largest holdings make up 24% of its $1.34T portfolio in Q4 2024.
- JP Morgan Chase opened 509 new positions and closed 522 in Q4 2024.
- JP Morgan Chase's portfolio value rose 2.1% quarter-over-quarter to $1.34T.
Based on JP Morgan Chase's 13F filing for Q4 2024, filed 12 Feb 2025.